The Bidens have convened a diverse board and staff with the goal of continuing efforts to accelerate research and development begun under the Cancer Moonshot Initiative.
Discover's D-brief blog ponders the future of the Cancer Moonshot initiative.
The law contains provisions that proponents say will advance precision medicine and speed new tests to market, but critics worry if this will come at a cost to public health.
Personalized medicine proponents are uncertain where funding, personnel, and priorities will land in a new administration and Congress.
NantHealth, CHOP, and their collaborators intend to release genomic, transcriptomic, and proteomic data from 1,600 patients in the next six months
The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.
Among the Blue Ribbon Panel's recommendations, several involve using molecular information to investigate the development and progression of cancer.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.